



## **FRALEX PROVIDES UPDATE ON RELIEF TRIAL**

**TORONTO, Ontario** – October 2, 2008 – Fralex Therapeutics Inc. (TSX: FXI) (“Fralex” or the “Company”), a medical technology company developing a treatment for chronic pain associated with fibromyalgia using a non-invasive neuromodulation device, today announced results from the interim analysis of its pivotal RELIEF trial.

The independent Data Monitoring Committee (“DMC”) for the RELIEF trial has notified Fralex management that the trial does not have the potential for a successful outcome based on the data from the first 100 patients.

“We are obviously disappointed by this outcome and will be moving to suspend the RELIEF trial immediately,” said Avi Grewal, President and CEO of Fralex.

### **About FRALEX:**

FRALEX is a medical technology company focused on developing and commercializing Complex Neural Pulse or CNP™, a novel neuromodulation therapeutic technology for chronic pain, which utilizes specifically designed, low-frequency electromagnetic pulses. For more information on FRALEX, please visit [www.fralex.com](http://www.fralex.com).

*Certain statements contained in this release containing words like "believe", "intend", "may", "expect", and other similar expressions, are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the Company's forward-looking statements include the following: market acceptance of the Company's technologies and products; the ability to obtain financing; the Company's financial and technical resources relative to those of its competitors; the Company's ability to keep up with rapid technological change; government regulation of therapeutic technologies; the Company's ability to enforce its intellectual property rights and protect its proprietary technologies; the ability to obtain and develop partnership opportunities; the timing of commercial product launches; the ability to achieve key technical milestones in key products and other risk factors identified from time to time in the Company's filings.*

### **For further information:**

Avi Grewal  
President and Chief Executive Officer  
Fralex Therapeutics Inc.  
(416) 213-8118 ext. 210  
[agrewal@fralex.com](mailto:agrewal@fralex.com)

Casey Gurfinkel  
Investor Relations  
The Equicom Group Inc.  
(416) 815-0700 ext. 283  
[cgurfinkel@equicomgroup.com](mailto:cgurfinkel@equicomgroup.com)